1. Scrip
  2. >>R&D
  3. >>Clinical Trials

Novartis Poised To Face Off With AstraZeneca In PNH After Second Iptacopan Trial

 
• By Jessica Merrill

The Phase III APPOINT-PNH study, testing iptacopan in treatment-naïve PNH patients, met its primary endpoint, positioning the oral drug as a potential new competitor to Soliris and Ultomiris.

dart board
Novartis said the second of two PHase III studies in PNH met their primary endpoint • Source: Shutterstock

Novartis AG has two successful Phase III clinical trials in hand for its targeted factor B inhibitor iptacopan in patients with paroxysmal nocturnal hemoglobinuria (PNH), positioning the drug for a regulatory filing in 2023 and eventually a commercial face off with AstraZeneca PLC's C5 inhibitors Soliris (eculizumab) and Ultomiris (ravulizumab).

The company announced on 8 December that the Phase III APPOINT-PNH study, testing iptacopan in treatment-naïve patients with PNH, was a success

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

Apnimed’s AD109 Could Be A Wake-Up Call For Sleep Apnea Market

 
• By Joseph Haas

The first of two Phase III trials in obstructive sleep apnea showed Apnimed’s combination pill can offer a therapeutic alternative to entrenched CPAP devices.

‘Unprecedented’ Data Lift AstraZeneca’s Ambitions For Airsupra

 
• By Kevin Grogan

The company hopes the drug will become the standard of care rescue treatment in asthma.

Pipeline Watch: Eight Approvals And Nineteen Phase III Readouts

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Leo Roars To A Profit In Q1 As Adbry Grows In US

 
• By Kevin Grogan

The Danish firm's atopic dermatitis drug is holding its own despite strong competition from Sanofi/Regeneron’s Dupixent.

More from R&D